Michał Wieliński

Managing Associate
Attorney-at-law

Capital Markets | Mergers and acquisitions (M&A) | Corporate law

Michał is an advocate specializing in capital markets and M&A law. He advises issuers of securities, financial institutions, sellers and both domestic and foreign investors.

Languages:

BIO

Joined GESSEL in 2021. His main area of expertise is capital market law. Michał advises on mergers and acquisitions and corporate disputes. He handles transactions related to raising equity and debt financing through issue of financial instruments. Advises on flotations on the Warsaw Stock Exchange and the NewConnect market. Handles transactions of primary and secondary public offerings (IPOs, SPOs), accelerated book-building processes (ABB), tender offers for sale of shares in public companies, delisting, squeeze-outs and buy-backs. Works for issuers, financial institutions, sellers and investors. Also advises on M&A transactions, supporting buyers, sellers and management of acquired companies.

Represents clients in proceedings before the Financial Supervision Authority, the Warsaw Stock Exchange board, and the National Depository for Securities. Advises on admission of financial instruments to public trading and their dematerialization.

Supports clients in significant corporate matters, including reorganization processes and the structuring and implementation of incentive programs. Attends meetings of corporate bodies. Serves as chairman of general meetings of public companies. Advises on the implementation of disclosure obligations.

Experience

Selected projects

  • Advised Cavatina Holding S.A. in an IPO transaction (transaction value of approximately PLN 187 mln)
  • Advised LUX MED sp. z o.o. in the acquisition of Swissmed Centrum Zdrowia S.A. (value of the transaction approximately PLN 60 mln)
  • Advised Wentworthtech sp. z o.o. and Savtec sp. z o.o. in the sale of a majority stake in Suwara S.A. (value of the transaction approximately PLN 100 mln)
  • Advised Vercom S.A. in an IPO transaction (transaction value of approximately PLN 225 mln)
  • Advised DataWalk S.A. on its public offering of shares (ABB) (value of the transaction approximately PLN 40 mln)
  • Advised Caspar Asset Management in the process of transferring its stock listing from the NewConnect market to the main floor of the Warsaw Stock Exchange
  • Advised Pure Biologics S.A. and shareholders in a public offering, a share lending transaction and a share sale at ABB (value of the transaction approximately PLN 30 mln)
  • Advised Elemental Holding S.A. in the compulsory buyout process of Elemental Asia S.A.
  • Advised LUX MED sp. z o.o. in the process of delisting Swissmed Centrum Zdrowia S.A. shares
  • Advised Urteste S.A. in its IPO and debut on the NewConnect market
  • Advised Erbud S.A. in a share buyback transaction
  • Advised Vercom S.A. in its acquisition of MailerLite (transaction value of about PLN 400 mln)
  • Advised Raya Holding in its acquisition of a significant stake in Makarony Polskie S.A.
  • Advised Comperia.pl in a share buyback transaction

News
& Insights

16.10.2023

We advised the WSE-listed company Creotech Instruments S.A.

We advised the WSE-listed company Creotech Instruments S.A. on a non-brokered public offering conducted under an accelerated bookbuilding procedure worth approximately P...

Case studies
We advised the WSE-listed company Creotech Instruments S.A.

05.07.2023

We advised WSE-listed Bioceltix S.A. on a non-brokered public offering of the Company’s shares

We advised WSE-listed Bioceltix S.A. on a non-brokered public offering of the Company's shares carried out under the accelerated book-building (ABB) procedure and a rela...

Case studies
We advised WSE-listed Bioceltix S.A. on a non-brokered public offering of the Company’s shares

26.06.2023

We advised WSE-listed Pure Biologics S.A. on a PLN 12 million financing transaction

We advised WSE-listed Pure Biologics S.A. in a transaction to raise PLN 12 million in financing from a new investor, ACRX Investments Ltd. The transaction was executed ...

Case studies
We advised WSE-listed Pure Biologics S.A. on a PLN 12 million financing transaction

23.06.2023

We advised WSE-listed Genomtec S.A. on a non-brokered public offering

We advised WSE-listed Genomtec S.A. on a non-brokered public offering of the company's shares carried out under an accelerated bookbuilding procedure (ABB) and a related...

News
We advised WSE-listed Genomtec S.A. on a non-brokered public offering
Show more

Education and achievements

  • Legal studies at the Faculty of Law and Administration of Adam Mickiewicz University in Poznań; Studies in international relations (international business and world economy at Adam Mickiewicz University in Poznań (2011)
  • British Law School organized by the British Law Centre (2012), study at Universiteit Gent in Belgium (Erasmus program, 2014)

Awards

Science publications